NYSE: CCChemours Co Stock
$33.64+6.53 (+24.09%)
Updated Jun 2, 2023
Chemours Company shares are trading... find out Why CC Price Moved with a free WallStreetZen account
Why Price MovedCC Price
$33.64
Fair Value Price
N/A
Market Cap
$5.02B
52 Week Low
$23.58
52 Week High
$44.95
P/E
10.45x
P/B
4.09x
P/S
0.68x
PEG
0.15x
Dividend Yield
2.97%
Revenue
$6.57B
Earnings
$489.00M
Gross Margin
22.8%
Operating Margin
12.14%
Profit Margin
7.4%
Debt to Equity
5.21
Operating Cash Flow
$633M
Beta
1.66
Next Earnings
Jul 26, 2023
Ex-Dividend
May 12, 2023
Next Dividend
Jun 15, 2023
CC Overview
The Chemours Company manufactures performance chemicals. Its segments include Titanium Technologies (titanium dioxide), Fluoroproducts (refrigerants and industrial fluoropolymer resins and derivatives including Freon, Teflon, Viton, Nafion, ECCtreme ECA, and Krytox), and Chemical Solutions (cyanide, sulfuric acid, aniline, methylamines, and reactive metals). Spun off from DuPont in 2015, Chemours is headquartered in Wilmington, DE.
Zen Score
–
Industry Average (40)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CC scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CC ($33.64) is trading below its intrinsic value of $97.34, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CC is good value based on its earnings relative to its share price (10.45x), compared to the US market average (52.69x)
P/E vs Market Valuation
CC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CC due diligence checks available for Premium users.
Be the first to know about important CC news, forecast changes, insider trades & much more!
CC News
Valuation
CC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
10.45x
Industry
23.3x
Market
52.69x
CC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.09x
Industry
3.56x
CC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CC price to earnings growth (PEG)
For valuing profitable companies with growth potential
CC is good value based... subscribe to Premium to read more.
PEG Value Valuation
CC's financial health
Profit margin
Revenue
$1.5B
Net Income
$145.0M
Profit Margin
9.4%
CC's Earnings (EBIT) of $797.00M... subscribe to Premium to read more.
Interest Coverage Financials
CC's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.6B
Liabilities
$6.4B
Debt to equity
5.21
CC's short-term assets ($3.20B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CC's long-term liabilities ($4.65B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$119.0M
Investing
-$97.0M
Financing
-$73.0M
CC's operating cash flow ($633.00M)... subscribe to Premium to read more.
Debt Coverage Financials
CC vs Specialty Chemical Stocks
Chemours Co Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.